hematologic malignancy

Allogeneic Stem Cell Transplantation After 70: Japanese Registry Data Define Who May Benefit Most

A Japanese registry study of 929 patients aged 70+ identified six predictors of worse survival after allo-HSCT and created a simple score that sharply stratified 2-year overall survival from 57.1% to 2.5%.